Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison) profile picture

Medical Science Liaison, Cardiovascular, Bristol Myers Squibb. Content is my own.

Bellingham, WA
Joined March 2009
Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)Photo by Erik Kellison, PharmD, BCPS, BCACP, BCCP (@erikkellison)
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
#COVID-19 as an endothelial disease. An insightful viewpoint from Peter Libby and @TomLuscher academic.oup.com/eurheartj/a… #cardiotwitter #CardioEd
22
29
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Don’t stop those ACEI and ARBS in the #COVID19 patients. Just released from the @escardio meetings. @ACCinTouch #ACCCVT @accpcardprn @JGPharmD
#ESCCongress | BRACE CORONA: heart patients hospitalised with #COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
2
15
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
DIGOXIN is BACK! #RateAF trial. RCT: Bisoprolol vs Digoxin in permAF: similar HR reduction, BUT better daily functioning, better NYHA class/NT-proBNP and less clinical events. #Epeeps #cardiotwitter #ESCCongress
1
29
4
63
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Inpatient initiation of sacubitril-valsartan for patients with HFrEF may be associated with reduced hospitalizations, increased quality-adjusted life expectancy, and cost savings compared with no initiation or initiation after hospitalization ja.ma/2CkHpfg
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Targeting #cardiovascular inflammation: next steps in clinical translation https://teapawt.net/t.co/Nm6ro3BlrS @escardio #EHJ #ESC_Young #cardiotwitter @ehj_ed
1
119
9
245
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Diagnose of #HFpEF is challenging. H2FPEF or HFA-PEFF scores might help to identify high risks in unexplained dyspnea. Great paper @mvaduganathan et al Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community heartfailure.onlinejacc.org/…
2
15
37
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
"Aortic stenosis is not a benign disease" @SachinGoelMD Angina = 5-year survival Syncope = 3-year survival CHF = 2-year survival https://teapawt.net/t.co/i6oj7BjgvA #CVBootcamp2020 #ahafit #ACCFIT #cardiotwitter #medtwitter #echofirst
1
17
43
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Open Access: A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. sciencedirect.com/science/ar…
1
22
3
60
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
A global approach with...EPA inside ! 😎 waiting for the pdf 👌 – at Paris, France
8
10
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Learning Diastolic Dysfunction can seem Overwhelming! But what if ANYONE could Learn/Understand #Diastology using a Simple "PUSH and PULL" Analogy? New Blog Post! Step By Step #POCUS Guide, PDF Pocket Card, & Calculator. 👉🔗pocus101.com/diastology #medtweetorial👇(1/18)
7
108
7
234
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Finally succceeded! Prague-17 trial, a comparison between left atrial appendage closure vs. non-vitamin k anticoagulants, was accepted today for publication in JACC ! A five year work 😁
20
34
1
260
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
New Review: cardiovascular effects and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) rdcu.be/b3IvH
1
29
4
36
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
ICYMI: Check out the key points to remember from this #JACCHF position paper on natriuretic peptides as inclusion criteria in clinical trials. Read here: https://teapawt.net/t.co/9V7PxEPNfC
6
2
18
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Mark your calendar for the FREE #ACC20/#WCCardio Virtual experience: March 28-30. Live access to 23 education sessions, such as LBCTs, Featured Clinical Research, Young Investigator Awards & keynotes. More here: https://teapawt.net/t.co/grLqqyP1wc
9
188
59
353
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://teapawt.net/t.co/ZkjPW6vDB7 #hypertension #cardiotwitter #Covid_19 #Covid19 #cardiology
1
113
51
169
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy https://teapawt.net/t.co/x0XS1hPszz @escardio @ehj_ed #EHJ #ESCYoung #cardiotwitter
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
COVID-19 and the cardiovascular system | Nature Reviews Cardiology short commentary on CV effects of COVID 19. Takeaways-Interesting pathway to effect heart.Pts with CVD at higher risk. If elevated troponins think myocarditis. #COVIDAndTheHeart nature.com/articles/s41569-0…
2
5
2
9
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
"Among clinically stable patients with chronic HF, majority of those with obesity demonstrated severe expansions in intravascular volume... [this] would appear to be a contributing mechanism to the development of an obesity-related HF phenotype." onlinejcf.com/article/S1071-…
4
1
11
Beautiful TOPCAT substudy in JACC: Heart Failure DOI: 10.1016/j.jchf.2019.09.009. By integrating clinical, imaging and multiple biomarker data, 3 distinct phenotypes identified. Tipe 1 not true HFPEF. Editorial: a must read. Self-explaining illustration. @pedschwartzmann
3
45
1
99
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
PROGRESS-HF Phase 2 Trial out now in @JCardFail. The trial evaluated the effects of elamipretide, a novel mitochondrial modulating agent, on LV function in HFrEF patients. Special thanks to @JavedButler1 and @Filippatos. See results below onlinejcf.com/#/article/S107…
3
12
2
31